Navigation Links
Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
Date:1/12/2009

anticipates ending 2009 with approximately $100 million in cash.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Amicus has a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire Limited, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

About Shire plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales f
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
2. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
3. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
4. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
5. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
6. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
7. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
10. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
11. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... TAIPEI , Sept. 1, 2015 ... (GNTbm) held a press conference in Taipei ... developments in its new Vaucarrin™ platform, a targeted drug ... vehicle. This event was part of a ... Gold NanoTech Inc. (GNT), showcasing GNT,s latest ...
(Date:9/1/2015)... Sept. 1, 2015 Sargas Pharmaceutical Adherence ... and Drug Adherence m Health applications along with ... process of non face-to-face monitoring of twenty minutes ... release of our apps, doctors are now well ... with our ONCHIT certified Physician, Pharmacy and Patient ...
(Date:9/1/2015)... -- Agena Bioscience TM today announced the establishment of ... and financial hub from which many biotech and life science ... mainland China . "The Chinese ... with almost sixty MassARRAY ® Systems installed to date. ... us to expand our reach and foster a high degree ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Agena Bioscience Opens Office in Shanghai, China 2
... 12 Research presented at the American College of ... that an intervention to reduce over-dispensing and waste of ... can result in substantial cost savings. , Medco Health ... of a study that examined the effectiveness and safety ...
... 12 /PRNewswire / -- New research findings ... (SIO) Sixth International Conference in New York show ... complementary and alternative medicine (CAM) using traditional research ... Children,s Hospitals and Clinics of Minnesota (Children,s), presented ...
Cached Medicine Technology:New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention 2New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention 3New Research Shows Promise in Using Traditional Research Methods to Assess Efficacy of Complementary Therapies 2
(Date:9/1/2015)... ... ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive session of its ... taken place at Kingsborough Community College in Brooklyn in each of the past three ... and two junior counselors who were campers themselves just a few years ago. , ...
(Date:9/1/2015)... ... September 01, 2015 , ... Georgia State ... universities across the country in stemming sexual assaults on their campuses. , The ... a consortium of sexual assault researchers and student affairs professionals responding to calls ...
(Date:9/1/2015)... ... September 01, 2015 , ... As ... Cross and Blue Shield of Minnesota (Blue Cross) has announced Doctor On Demand ... in San Francisco, Doctor On Demand provides immediate access to Board Certified physicians ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... “Hair Extension Vending Machine,” is still strongly maintaining her firm’s success in the ... beauty tools. In her upcoming city-to-city tour, Ellis will be providing “Look and ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... that Edge Information Management has been granted continued accreditation based on a ... , “Achieving and maintaining this accreditation takes the involvement and dedication ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3
... and civil society representatives joined hands today to boost ... to tackle HIV/AIDS. // ,Headed by C ... Prime Minister, the 10-member independent commission on AIDS in ... of the developmental consequences of AIDS in the region ...
... a ban by the government, asbestos might still be ... the toxic mineral on a large scale, a Canadian ... activist working on mining issues in Canada for 12 ... connected with asbestos mining. ,Palu, accompanied by ...
... administration has issued a warning to consumers to stay ... allegedly capable of enhancing// the sexual experience. According ... which may trigger a host of health complications. ... Zimaxx, Libidus, Neophase, Nasutra, Vigor-25, Actra-Rx and 4EVERON. ...
... clitoris is practiced as an initiation rite for women ... A senior doctor sounds// off that instead of blaming ... sorting out the aesthetic procedure seeks prime importance. ... that the procedure of mutilation performed among girls and ...
... has revealed that gene mutations that are responsible for ... syndrome (RTT) in females are not always lethal// in ... and can occur sporadically in infant males without a ... the journal Neurology reports four sporadic occurrences of MECP2 ...
... available throughout the country to manage over six million ... of Madras ENT Rearch Foundation Charitable Trust Mohan Kameshwaran ... were concentrated in major cities, which made treatment and ... prior to the inauguration of the MERF Institute of ...
Cached Medicine News:Health News:Despite Ban, Asbestos Produce Goes Unhindered 2Health News:Gene Mutations Causing Rett Syndrome Occur in Both Sexes 2Health News:Gene Mutations Causing Rett Syndrome Occur in Both Sexes 3
Straight shafts with 0.12 mm teeth and tying platform. Serrated handle with polished finish....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Medicine Products: